KO Client Nanospectra Closes $3 Million Series B-1 Financing

KO client Nanospectra Biosciences, a medical device company that is pioneering a novel use of nanomedicine to destroy tumors without damaging adjacent healthy tissue, recently closed a $3 million Series B-1 financing with total approved capital of up to $6 million.

The financing will be used for additional development and commercialization of Nanospectra’s lead product AuroLase®, which is the first and only ultra-focal ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation and alternative focal therapies.

KO partner John Gaddis, attorney Ian Kuliasha and corporate paralegals Caitlyn Knudson and Chris Ignelzi represented Nanospectra in the financing.

Read more in Medical Device Network.